<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Endocr Rev</journal-id>
<journal-id journal-id-type="iso-abbrev">Endocr. Rev</journal-id>
<journal-id journal-id-type="publisher-id">edrv</journal-id>
<journal-title-group>
<journal-title>Endocrine Reviews</journal-title>
</journal-title-group>
<issn pub-type="ppub">0163-769X</issn>
<issn pub-type="epub">1945-7189</issn>
<publisher>
<publisher-name>Endocrine Society</publisher-name>
<publisher-loc>Washington, DC</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30124805</article-id>
<article-id pub-id-type="pmc">6260247</article-id>
<article-id pub-id-type="publisher-id">edrv_201800139</article-id>
<article-id pub-id-type="doi">10.1210/er.2018-00139</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
<subj-group subj-group-type="category-toc-heading">
<subject>Adrenal</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-0314-9252</contrib-id>
<name>
<surname>Vaidya</surname>
<given-names>Anand</given-names>
</name>
<!--<email>anandvaidya@bwh.harvard.edu</email>-->
<xref ref-type="corresp" rid="c1"></xref>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mulatero</surname>
<given-names>Paolo</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baudrand</surname>
<given-names>Rene</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Adler</surname>
<given-names>Gail K</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label>Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts</aff>
<aff id="aff2"><label>2</label>Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Torino, Torino, Italy</aff>
<aff id="aff3"><label>3</label>Program for Adrenal Disorders and Hypertension, Department of Endocrinology, Pontificia Universidad Catolica de Chile, Santiago, Chile</aff>
<author-notes>
<corresp id="c1"><bold><italic>Correspondence and Reprint Requests:</italic></bold> Anand Vaidya, MD MMSc, Center for Adrenal Disorders, Brigham and Women’s Hospital, Division of Endocrinology, Diabetes, and Hypertension, 221 Longwood Avenue, Boston, Massachusetts 02115. E-mail: <email>anandvaidya@bwh.harvard.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="collection">
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date iso-8601-date="2018-08-15" pub-type="epub">
<day>15</day>
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>12</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="collection"/>. -->
<volume>39</volume>
<issue>6</issue>
<fpage>1057</fpage>
<lpage>1088</lpage>
<history>
<date date-type="received">
<day>13</day>
<month>5</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>8</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 Endocrine Society</copyright-statement>
<copyright-year>2018</copyright-year>
</permissions>
<self-uri xlink:href="er.2018-00139.pdf"></self-uri>
<abstract>
<title>Abstract</title>
<p>Primary aldosteronism is characterized by aldosterone secretion that is independent of renin and angiotensin II and sodium status. The deleterious effects of primary aldosteronism are mediated by excessive activation of the mineralocorticoid receptor that results in the well-known consequences of volume expansion, hypertension, hypokalemia, and metabolic alkalosis, but it also increases the risk for cardiovascular and kidney disease, as well as death. For decades, the approaches to defining, diagnosing, and treating primary aldosteronism have been relatively constant and generally focused on detecting and treating the more severe presentations of the disease. However, emerging evidence suggests that the prevalence of primary aldosteronism is much greater than previously recognized, and that milder and nonclassical forms of renin-independent aldosterone secretion that impart heightened cardiovascular risk may be common. Public health efforts to prevent aldosterone-mediated end-organ disease will require improved capabilities to diagnose all forms of primary aldosteronism while optimizing the treatment approaches such that the excess risk for cardiovascular and kidney disease is adequately mitigated. In this review, we present a physiologic approach to considering the diagnosis, pathogenesis, and treatment of primary aldosteronism. We review evidence suggesting that primary aldosteronism manifests across a wide spectrum of severity, ranging from mild to overt, that correlates with cardiovascular risk. Furthermore, we review emerging evidence from genetic studies that begin to provide a theoretical explanation for the pathogenesis of primary aldosteronism and a link to its phenotypic severity spectrum and prevalence. Finally, we review human studies that provide insights into the optimal approach toward the treatment of primary aldosteronism.</p>
</abstract>
<funding-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">National Institutes of Health</named-content>
<named-content content-type="funder-identifier">10.13039/100000002</named-content>
</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="32"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>